Singapore markets close in 4 hours 53 minutes

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.8014-0.0246 (-2.98%)
At close: 04:00PM EDT
0.7900 -0.01 (-1.42%)
After hours: 07:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.8260
Open0.8110
Bid0.7979 x 200
Ask0.8065 x 200
Day's range0.8000 - 0.8340
52-week range0.6700 - 3.1300
Volume418,789
Avg. volume777,488
Market cap60.127M
Beta (5Y monthly)0.46
PE ratio (TTM)N/A
EPS (TTM)-1.4000
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est11.67
  • Insider Monkey

    13 Best Penny Stocks to Buy According to Billionaire Ken Griffin

    In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to Billionaire Ken Griffin. The markets were off to an impressive start in 2024, driven by expectations that the […]

  • Business Wire

    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., April 08, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,000 shares of its common stock with an exercise price of $0.93 per share, which is equal to the closing price of Kezar’s common stock on April 1, 2

  • Business Wire

    Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., March 14, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.